Skip to main content
SpringerLink
Log in

NAFLD, diabete tipo 2, rischio cardiovascolare?

  • Rassegna
  • Published:
L'Endocrinologo Aims and scope

Sommario

La steatosi epatica non alcolica (NAFLD) è attualmente l’epatopatia cronica più comune nella pratica clinica. La prevalenza della NAFLD è assai elevata nel diabete tipo 2 (T2D), essendo presente in oltre il 60–70% di tali pazienti. In questa breve rassegna discuteremo le evidenze clinico-epidemiologiche che suggeriscono una significativa associazione tra NAFLD e aumentato rischio di complicanze cardiovascolari nel T2D e i possibili meccanismi fisiopatologici che spiegano tale associazione.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Bibliografia

  1. Younossi Z, Anstee QM, Marietti M et al. (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15:11–20

    Article  PubMed  Google Scholar 

  2. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64:1388–1402

    Google Scholar 

  3. Chalasani N, Younossi Z, Lavine JE et al. (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357

    Article  PubMed  Google Scholar 

  4. Lonardo A, Bellentani S, Argo CK et al. (2015) Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis 47:997–1006

    Article  PubMed  Google Scholar 

  5. Targher G, Day CP, Bonora E (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363:1341–1350

    Article  CAS  PubMed  Google Scholar 

  6. Targher G, Lonardo A, Byrne CD (2018) Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 14:99–114

    Article  CAS  Google Scholar 

  7. Targher G, Bertolini L, Padovani R et al. (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:1212–1218

    Article  PubMed  Google Scholar 

  8. Anstee QM, Targher G, Day CP (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10:330–344

    Article  CAS  Google Scholar 

  9. de Marco R, Locatelli F, Zoppini G et al. (1999) Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 22:756–761

    Article  PubMed  Google Scholar 

  10. Italian Association for the Study of the Liver (AISF) (2017) AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. Dig Liver Dis 49:471–483

    Article  Google Scholar 

  11. Zhou YY, Zhou XD, Wu SJ et al. (2018) Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis. Hepatol Commun 2:376–392

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Targher G, Byrne CD, Lonardo A et al. (2016) Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 65:589–600

    Article  Google Scholar 

  13. Mantovani A, Pernigo M, Bergamini C et al. (2015) Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism 64:879–887

    Article  CAS  PubMed  Google Scholar 

  14. Anstee QM, Mantovani A, Tilg H et al. (2018) Risk of cardiomyopathy and cardiac arrhythmias in patients with non-alcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 15(7):425–439

    Article  PubMed  Google Scholar 

  15. Targher G, Valbusa F, Bonapace S et al. (2013) Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS ONE 8:e57183

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Mantovani A, Rigamonti A, Bonapace S et al. (2016) Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour holter monitoring. Diabetes Care 39:1416–1423

    Article  CAS  PubMed  Google Scholar 

  17. Francque SM, van der Graaff D, Kwanten WJ (2016) Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol 65:425–443

    Article  CAS  PubMed  Google Scholar 

  18. Lonardo A, Nascimbeni F, Mantovani A et al. (2018) Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol 68:335–352

    Article  PubMed  Google Scholar 

  19. Angulo P, Kleiner DE, Dam-Larsen S et al. (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149:389–397

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sezione di Endocrinologia, Diabetologia e Malattie del Metabolismo, Dipartimento di Medicina, Università e Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italia

    Alessandro Mantovani, Riccardo Rigolon, Teresa Turino, Isabella Pichiri & Giovanni Targher

Authors
  1. Alessandro Mantovani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riccardo Rigolon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Teresa Turino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Isabella Pichiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giovanni Targher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Targher.

Ethics declarations

Conflitto di interesse

Gli autori Alessandro Mantovani, Riccardo Rigolon, Teresa Turino, Isabella Pichiri e Giovanni Targher dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi su animali.

Additional information

Proposto da Riccardo Bonadonna.

Materiale elettronico supplementare

I link al materiale elettronico supplementare sono elencati qui sotto.

(DOC 26 kB)

(DOC 28 kB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mantovani, A., Rigolon, R., Turino, T. et al. NAFLD, diabete tipo 2, rischio cardiovascolare?. L'Endocrinologo 19, 255–259 (2018). https://doi.org/10.1007/s40619-018-00478-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-018-00478-w

Parole chiave

Search

Navigation